Potential conflict of interest: Nothing to report.
This work was supported by a Grant-in-aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control, the CREST program from the Japan Science and Technology Agency, a Grant-in-Aid for hepatitis B virus research from the Ministry of Education, Culture, Sports, Science, and Technology, the A-STEP program of the Japanese Science and Technology Agency, the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio), the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), and the Japan Society for the Promotion of Science (JSPS) through its “Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program).” This work was also carried out by the joint research program of the Institute for Molecular and Cellular Regulation, Gunma University (Maebashi, Japan).
Address reprint requests to: Takahiro Ochiya, Ph.D., Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: email@example.com; fax: +81-3-5565-0727.
MicroRNAs (miRNAs) are evolutionary conserved small RNAs that post-transcriptionally regulate the expression of target genes. To date, the role of miRNAs in liver development is not fully understood. By using an experimental model that allows the induced and controlled differentiation of mouse fetal hepatoblasts (MFHs) into mature hepatocytes, we identified miR-148a as a hepatospecific miRNA highly expressed in adult liver. The main finding of this study revealed that miR-148a was critical for hepatic differentiation through the direct targeting of DNA methyltransferase (DNMT) 1, a major enzyme responsible for epigenetic silencing, thereby allowing the promotion of the “adult liver” phenotype. It was also confirmed that the reduction of DNMT1 by RNA interference significantly promoted the expression of the major hepatic biomarkers. In addition to the essential role of miR-148a in hepatocyte maturation, we identified its beneficial effect through the repression of hepatocellular carcinoma (HCC) cell malignancy. miR-148a expression was frequently down-regulated in biopsies of HCC patients as well as in mouse and human HCC cell lines. Overexpressing miR-148a led to an enhancement of albumin production and a drastic inhibition of the invasive properties of HCC cells, whereas miR-148a silencing had the opposite consequences. Finally, we showed that miR-148a exerted its tumor-suppressive effect by regulating the c-Met oncogene, regardless of the DNMT1 expression level. Conclusion: miR-148a is essential for the physiology of the liver because it promotes the hepatospecific phenotype and acts as a tumor suppressor. Most important, this report is the first to demonstrate a functional role for a specific miRNA in liver development through regulation of the DNMT1 enzyme. (Hepatology 2013;53:1153–1165)
MicroRNAs (miRNAs) constitute a group of evolutionary conserved small noncoding RNA molecules that finely regulate gene expression by complementary base pairing with the 3'-untranslated regions (3'-UTRs) of target messenger RNAs (mRNAs). The past decades have seen an increasing recognition of the overall significance of miRNAs in regulating a wide variety of fundamental biological phenomena and diseases,[1, 2] including cancer.[3-5] The functional significance of miRNAs in cell specification and vertebrate development has been recently tackled. For instance, miR-124 and miR-9,[7, 8] two brain-enriched miRNAs, appear to be essential in neurogenesis, whereas miR-27b is relevant for myogenesis. To date, little is known regarding the role and function of miRNAs in liver development. Hand et al. provided the first link between miRNAs and hepatobiliary development by emphasizing the functional role of miR-30a during biliary morphogenesis in zebrafish. In humans, miR-122 might be of prime interest because it represents more than 70% of the total amount of miRNAs expressed in the adult liver, where it acts in metabolism regulation and hepatic homeostasis.
During development, epigenetic modifications are essential for the modulations of tissue-specific gene expression that promote cell differentiation. Epigenetic silencing includes reversible DNA methylation, which is primarily orchestrated by DNA methyltransferases (DNMTs). DNMT1 represents the major enzyme responsible for the maintenance of DNA methylation patterns during replication. In contrast, DNMT3a and DNMT3b have been identified as de novo methyltransferases, which methylate DNA during early development and gametogenesis, although DNMT1 also possesses de novo methylation activity. Inactivation of the DNMT1 enzyme in mice results in loss of genomic imprinting and leads to early embryonic lethality. In addition, studies using methylation-deficient mouse embryos (Dnmt1−/−, Dnmt3a−/−, and Dnmt3b−/−) have demonstrated that restoring DNA methylation is essential for development.[14, 16] More recently, Sen et al. observed the enrichment of DNMT1 protein in epidermal progenitors, where it is required to maintain proliferative strength and suppress differentiation. Their study also showed that DNMT1 depletion was associated with the altered proliferation and transition from progenitors to premature epidermal cells. In the liver, DNMT1 expression is frequently increased in tissues affected by chronic hepatitis and cirrhosis and, more dramatically, in hepatocellular carcinoma (HCC), in which DNMT1 augmentation correlates with poor prognosis.[18, 19]
This study aimed to investigate the potential role of miRNAs in hepatic development. By taking advantage of an experimental primary cell-culture model that can trigger hepatic differentiation, we performed mouse miRNA microarray analyses and identified 10 miRNAs, which were selected for their predicted aptitude to target DNMT1. Among those miRNAs, miR-148a showed a strong induction in differentiating liver progenitors. Conversely, DNMT1 expression presented a rapid decline after stem cell entry into the differentiation process. We reported a correlation between the elevation of miR-148a and the promotion of the hepatospecific phenotype through the silencing of DNMT1. Because a significant down-regulation of miR-148a was observed in HCC, the role of miR-148a in liver cancer was also considered. We demonstrated the ability of miR-148a to suppress the invasive properties of transformed hepatic cells by inhibiting c-Met expression. In line with these findings, miR-148a was shown to play an essential role in the fate of the liver by inducing hepatospecific gene expression and suppressing tumor cell invasion.
Material and Methods
Mouse Fetal Hepatoblast Model
Mouse fetal hepatoblasts (MFHs) were isolated and triggered to differentiate into mature hepatocytes as previously described. Briefly, the method was based on the selective harvesting of hepatic parenchymal stem cells from mouse fetuses (E14.5). After their isolation, fetal liver tissues were dissociated physically and enzymatically in the presence of liberase (Liberase TM Research Grade; Roche Diagnostics, Mannheim, Germany). The sorting of epithelial cadherin (E-cadherin)-positive progenitors was performed using the biotin anti-CD324 (E-cadherin) antibody (Ab) (eBioscience, Inc., San Diego, CA) and the EasySep Mouse Biotin Positive Selection Kit (STEMCELL Technologies Inc., Vancouver, British Columbia, Canada). From seeding, MFHs were maintained in a medium composed of the following mixture: William's E Medium, L-glutamine (2 mM), penicillin (50 IU/mL), and streptomycin (50 µg/mL), all from Gibco (Grand Island, NY), insulin (5 µg/mL; Sigma-Aldrich, St. Louis, MO), epidermal growth factor (25 ng/mL; Sigma-Aldrich), and 10% fetal bovine serum (FBS; HyClone; Thermo Fisher Scientific, Waltham, MA) supplemented with essential hepatocyte phenotype-promoting factors, including hepatic growth factor (HGF; 25 ng/mL; PeproTech Inc., Rocky Hill, NJ), oncostatin M (12.5 ng/mL; Sigma-Aldrich), hydrocortisone 21-hemisuccinate (5 × 10−7 M; Sigma-Aldrich), and dexamethasone (10−7 M; Sigma-Aldrich). The medium was replaced daily.
HCC Cell Lines and Human Samples
Mouse Hepa 1-6 and human HepG2 and Hep3B cells were purchased from the American Type Culture Collection (Manassas, VA). Huh-7 cells were from Riken BioResource Center (RIKEN BRC, Ibaraki, Japan). Cells were maintained in Dulbecco's modified Eagle's medium (Gibco) supplemented with penicillin (100 IU/mL), streptomycin (100 µg/mL), and 10% FBS. Human samples included 39 pairs of primary HCCs and their corresponding nontumor tissues. All patients exhibited chronic liver disease (CLD) related to hepatitis B (HBV) or C virus (HCV) infection (n = 18 and 21, respectively). Normal liver samples were collected from patients who had surgical resection of metastasis in the liver. Human fetal livers were obtained from spontaneously aborted fetuses (see Supporting Table 2 for clinical data).
miRNA and small interfering RNA (siRNA) transfection procedures for primary cultures and cell lines, DNA extraction, methylation assay, immunoblotting, total RNA extraction, miRNA microarray, miRNA, and mRNA expression analysis by reverse-transcription quantitative polymerase chain reaction (RT-qPCR), miRNA assessment in the serum of HCC patients, periodic acid-Schiff (PAS) staining, luciferase reporter assays, apoptotic activity, cell growth, wound healing, transwell invasion assays, and statistical tools are described in the Supporting Materials.
MFH Is an Adequate Model for the Study of Hepatic Differentiation
To clarify the function of miRNAs in liver development, we used an in vitro model previously developed by our group based on the sorting of E-cadherin-positive fetal liver cells, called MFHs, and their induced differentiation into hepatocytes (Fig. 1A). MFHs underwent remarkable changes in morphology during the maturation-induced process that resulted in the formation of pronounced cell aggregates with cuboidal shape, polarity, and frequent binucleation (Fig. 1B). Importantly, mature-induced hepatocytes exhibited prominent glycogen storage ability. The molecular data were consistent with those observations and revealed a hepatospecific phenotype and progressive maturation of MFHs, as evidenced by the expression of the early (alpha-fetoprotein; Afp), mid- (albumin; Alb), and late (glucose-6-phosphatase [G6pc] and tyrosine aminotransferase [Tat]) hepatic markers (Fig. 1C). In addition, the major cytochrome P450s (CYPs) were similarly induced (Supporting Fig. 1). Conversely, the mRNA level of cytokeratin 19 (Ck19), which is commonly associated with liver stem cells and epithelial cells of the biliary tract, decreased rapidly after the initiation of the maturation process. Our data also indicate the rapid decline of Dnmt1 expression in association with MFH differentiation, whereas Dnmt3a and Dnmt3b increased progressively (Fig. 1D).
miR-148a Induction Is Observed in Hepatic Cells During Mouse Liver Development
To analyze the expression profile of miRNAs during hepatic differentiation, we performed an miRNA microarray by using the MFH model at different stages of maturation (Fig. 2A; all the miRNA microarray data are displayed in Supporting Table 1). Then, taking advantage of the combination of the publicly available search engines, miRNA (miRanda), TargetScan, and PicTar, we obtained a list of 12 miRNAs that could putatively target Dnmt1 (Table 1). Among those miRNAs, 10 were significantly expressed in differentiating MFHs. A family of three conserved miRNAs (miR-148a, miR-148b, and miR-152) was highlighted as a result of its remarkable expression pattern during the maturation process of MFHs (Fig. 2B). More explicitly, both microarray and RT-qPCR analyses revealed that miR-148a and miR-152 were gradually up-regulated from the MFH to the mature-induced hepatocyte stage (Fig. 2C). In contrast, miR-148b stayed unchanged. Obviously, miR-148a exhibited the most significant induction and highest expression level in mature hepatocytes. Similar profiles of expression for these miRNAs were obtained from fetal liver tissues during mouse development (Supporting Fig. 2). In addition, Dnmt1 expression was inversely correlated with the level of miR-148a in both in vitro and in vivo models, whereas Dnmt3a and Dnmt3b did not correlate. Consequently, it was hypothesized that miR-148a could play a critical role in liver development by regulating Dnmt1 expression.
Table 1. List of the miRNAs That Are Predicted to Target Mouse Dnmt1 and Their Respective Expression in the MFH Model (miRNA Microarray Data)
miR-148a Is Down-regulated in Human and Rodent HCC Cells
To explore the significance of miR-148a in the liver, we first compared expression profiles of miR-148a among mature-induced hepatocytes (MFH D8), undifferentiated hepatic stem cells (MFH D2), and the mouse HCC cell line, Hepa 1-6. Human Huh-7, HepG2, and Hep3B cells were also characterized in regard to normal adult and fetal hepatic tissues. As a result, a dramatic diminution of miR-148a was observed in both rodent (Fig. 3A) and human cell lines as well as in fetal livers (Fig. 3B). Moreover, the reduced expression of miR-148a was consistent with Dnmt1 augmentation in both species, arguing for a probable connection between miR-148a and Dnmt1. Thus, Spearman's rank correlation analysis showed that expression levels of DNMT1 and miR-148a in human samples were inversely correlated (rho: −0.609; P = 0.0034; Fig. 3C). To test the functional relevance of miR-148a down-regulation caused by DNA methylation, HCC cells were exposed to 5-Aza-2'-deoxycytidine (5-Aza). We found that demethylation treatment dramatically restored miR-148a expression in a dose-response manner in both Hepa 1-6 and HepG2 cell lines (Fig. 3D), indicating that a hypermethylation phenomenon is most likely responsible for the silencing of miR-148a in liver cancer cells. To verify this hypothesis, we first analyzed the genomic DNA sequence spanning of miR-148a and found that this gene had many CpG-rich regions (CpG islands) in its promoter. Subsequently, combined bisulfite restriction analysis (COBRA) was performed to examine the methylation status of the miR-148a promoter, which revealed hypermethylation of CpG islands in the miR-148a promoter in HepG2 cells, compared to normal human hepatocytes (Fig. 3E). We also observed that demethylation treatment by 5-Aza dramatically decreased the methylation status of the miR-148a promoter in both human and rodent HCC cell lines. Although the COBRA method did not reveal demethylation of the analyzed miR-148a CpG sites during the maturation process of MFHs (Supporting Fig. 3), bisulfite sequencing showed that the average methylation level of miR-148a was higher in undifferentiated MFHs (17.6% in MFH_D2), compared to differentiating cells (5.7% in MFH_D4), suggesting that a hypermethylation mechanism may participate in the regulation of miR-148a expression during development.
miR-148a Directly Modulates Dnmt1 Expression
We postulated that Dnmt1 inhibition during MFH maturation could be the result of its direct targeting by miR-148a. To explore this possibility, we first analyzed the consequences of miR-148a silencing or overexpression in HCC cell lines. The use of miR-148a mimics clearly affected Dnmt1 expression (Fig. 4A). Conversely, we observed a significant enhancement of Dnmt1 level after transfection with miR-148a antagonists up to 72 hours post-transfection. Dnmt1 contains a 3'-UTR element that is partially complementary to miR-148a in both rodent and human species (Fig. 4B). The miRNA prediction databases that we interrogated identified Dnmt1 as a high-scoring predicted target of miR-148a. Simultaneous transfection with miRNA mimics and a construct containing the mouse Dnmt1 3'-UTR inserted downstream of the luciferase coding sequence was performed in Hepa 1-6 cells. In this assay, miR-148a-forced expression decreased luciferase activity by 43.2% ± 1.1% (P < 0.001) from the control value, whereas it failed to inhibit reporter activity in cells transfected with the vector containing a mutated sequence of the Dnmt1 3'-UTR (Fig. 4B). Comparable data were obtained using the 3'-UTR of human DNMT1 transfected into the human HCC cell line, HepG2. Then, to explore the role of DNMT1 in regulating expression of miR-148a, we silenced DNMT1 by using a siRNA approach in Hepa 1-6 and HepG2 cells. Both mouse Dnmt1 knockdown and human DNMT1 knockdown significantly induced miR-148a expression (Fig. 4C), reinforcing the idea of a regulatory circuit between DNMT1 and miR-148a as well as the existence of epigenetic regulation exerted by DNMT1 on miR-148a.
miR-148a Enhancement Promotes Hepatospecific Gene Expression Through Dnmt1 Inhibition During the Induced Differentiation of MFHs Into Mature Hepatocytes
The influence of miR-148a in hepatic differentiation was investigated by forcing its expression in the MFH primary culture model and evaluating the expression of major liver markers. Cells transfected with miR-148a mimics exhibited substantial overexpression of miR-148a, in contrast to its normal expression profile during MFH differentiation (Fig. 5A). Immunoblotting revealed that miR-148a overexpression dramatically increased the protein level of Alb in MFHs (Fig. 5B). The methylation status of the Alb promoter was also explored, which showed a progressive demethylation of CpG islands during hepatic differentiation (Supporting Fig. 3). Both 5-Aza treatment and miR-148a mimics contributed to the demethylation of Alb promoter, indicating the possible regulation of Alb expression by miR-148a through an epigenetic mechanism involving Dnmt1. RT-qPCR analysis demonstrated that miR-148a mimics enhanced the mRNA levels of Alb as well as the other major hepatic biomarkers, G6pc and Tat, whereas cells transfected by the control showed the standard differentiation process induced by the hepatotrophic factors (Fig. 5C). Moreover, miR-148a augmentation had no effect on Ck19 expression in MFHs, but it was associated with the increased expression of various CYPs (Supporting Fig. 4). Remarkably, we found evidence that miR-148a restoration in both mouse Hepa 1-6 and human HepG2 HCC cell lines was significantly related with the inhibition of the immature liver marker, Afp, whereas Alb expression was strongly enhanced, and vice versa (Fig. 4A). Last, the forced expression of miR-148a was correlated with a drastic repression of Dnmt1 in both the HCC (Fig. 4A) and MFH models (Fig. 5C). Western blotting analysis confirmed the negative correlation between miR-148a and DNMT1 expression levels (Fig. 5B). Indeed, the transfection of MFHs using miR-148a mimics promoted the decline of Dnmt1 that is normally observed during the differentiation process of these cells. To address the involvement of Dnmt1 in the establishment of the hepatic phenotype through its modulation by miR-148a, we finally analyzed the effect of Dnmt1 knockdown in the induced differentiation of MFHs. Consistent with miR-148a overexpression data, Dnmt1 inhibition led to the significant promotion of the major hepatic biomarkers that we assessed (Fig. 5D). Compared with MFHs transfected with negative control siRNAs, mRNA levels of Alb and advanced maturation biomarkers (G6pc, Tat, and Cyp17a1) appeared to be globally up-regulated 72 hours after Dnmt1 siRNA transfection.
In summary, these findings implicate Dnmt1 in the mechanisms controlling liver precursor maturation and indicate that miR-148a promotes the expression of adult hepatic genes by repressing Dnmt1 (Fig. 5E). In contrast, the occurrence of HCC malignancy may be associated with the deregulation of miR-148a, whereas maintenance of this miRNA seems to be essential for preserving the hepatospecific status of liver cells.
miR-148a Expression Is Frequently Decreased in the Liver of HCC Patients
We analyzed miR-148a expression in a cohort of 39 pairs of primary HCCs related to HBV or HCV infection and their adjacent nontumor regions. Tissues from normal liver (n = 13) were used as controls. miR-148a expression was reduced by more than 5-fold in HCC biopsies, relative to the normal liver group (median, 0.293 and 1.674, respectively; P < 0.0001, Mann-Whitney's U test; Fig. 6A). Interestingly, miR-148a was also inhibited in peritumoral non-neoplastic tissues, but to a lesser extent (median, 0.403; P < 0.001). We confirmed the possible correlation between miR-148a inhibition and advancement of the underlying liver disease by analyzing the expression level of miR-148a between early (chronic hepatitis) and advanced (precirrhotic/cirrhotic) fibrosis in nontumor tissues (Fig. 6B). Expression of miR-148a was significantly decreased in the cirrhotic samples, compared to the chronic hepatitis liver group (median, 0.247 and 0.473, respectively; P < 0.0001, Mann-Whitney's U test). Then, DNMT1 levels between tumors and their adjacent tissues were evaluated (Fig. 6C). Although DNMT1 expression was significantly down-regulated in tumors (P = 0.0002, Wilcoxon's signed-rank test), statistical analysis did not reveal significant correlation between DNMT1 and miR-148a expression in those clinical samples. Next, we compared the expression of miR-148a between tumors and their pair-matched normal tissues (Supporting Fig. 5). Of the 18 HBV-related HCC samples, miR-148a expression was decreased in 15 tumors, relative to their adjacent noncancerous hepatic regions (P = 0.0268, Wilcoxon's signed-rank test). In the 21 HCV-related HCCs, inhibition of miR-148a was observed in 12 HCC samples (P = 0.9308). The value of circulating miR-148a as a noninvasive HCC recurrence diagnostic marker in blood serum was also evaluated. Samples were collected in two steps from 11 HCC patients with HCV infection: (1) after surgical resection of the primary tumor and (2) subsequent to the diagnosis of HCC recurrence. We observed a diminution of circulating miR-148a in 8 patients after HCC recurrence (P = 0.2783, Wilcoxon's signed-rank test; Supporting Fig. 6).
The Rescue of miR-148a Suppresses HCC Cell Migration and Invasion by Indirectly Inhibiting the Hepatocyte Growth Factor Receptor Oncogene
As we highlighted the crucial role played by miR-148a in normal hepatic differentiation, it was of significant interest to consider the possible relationship between miR-148a deregulation and the promotion of hepatocyte transformation. First, the phenotype of Hepa 1-6 cells was characterized after the forced expression of miR-148a to investigate the effect of this miRNA on HCC cells. Notably, cell proliferation was not significantly altered by miR-148a mimics or antagonists (Fig. 7A), and induction of miR-148a had no effect on caspase activity (Supporting Fig. 7). However, the enforced expression of miR-148a substantially suppressed the motility of HCC cells in a wound-healing assay, whereas miR-148a agonists enhanced the recolonization of the wounds (Fig. 7B). In addition, overexpression of miR-148a remarkably altered the invasive abilities of Hepa 1-6 cells (51.6% ± 10.15% inhibition; P < 0.001), as revealed by the transwell migration assay (Fig. 7C). A similar observation was conducted using the human HCC cell line, Hep3B (data not shown). To evaluate whether the effect of miR-148a in the invasion of HCC cells is mediated by DNMT1 or another specific gene, functional analyses were performed using siRNA. We decided to focus on DNMT1 and hepatocyte growth factor receptor (c-Met), a frequently overexpressed oncogene in liver cancer and predicted target of miR-148a that was up-regulated in undifferentiated MFHs and Hepa 1-6 HCC cells (Supporting Fig. 8). In the presence of miR-148a mimics, c-Met mRNA levels appeared markedly decreased in Hepa 1-6, whereas miR-148a agonists promoted c-Met expression (Fig. 7D). However, c-Met 3'-UTR assays did not show a reduction of luciferase activity (Supporting Fig. 8), supporting an indirect effect of miR-148a on c-Met expression. Knockdown of c-Met using two distinct siRNAs attenuated cell proliferation (Fig. 7E) and dramatically abolished HCC cell invasion (78.8% ± 7.7% and 76.5% ± 7.5% inhibition, respectively; P < 0.001; Fig. 7F). Remarkably, the use of siRNAs targeting Dnmt1 did not modify cell proliferation or invasion. These last results strongly suggest that miR-148a plays two distinct roles in the liver: (1) in the control of hepatic development by regulating DNMT1 and (2) in the modulation of HCC cell invasiveness by repressing the c-Met oncogene.
DNA methylation plays an essential role in regulating stem cell differentiation and embryo development. Recently, Tsai et al. demonstrated that the pluripotency genes, Oct4 and Nanog, which constitute a fundamental regulatory mechanism suppressing differentiation-associated genes, directly bind to the promoter of DNMT1 and enhance its expression. In their report, mesenchymal stem cells exhibited a decreased proliferation rate when treated with an inhibitor of DNA methylation or transfected with DNMT1 short hairpin RNA, whereas the expression of genes associated with development regulators was increased. In agreement with this current work, our data clearly show the contribution of the DNMT1 enzyme in liver cell stemness as well as the existence of a micromanagement of DNMT1-related hepatic maturation controlled by miR-148a.
The deleterious consequences of DICER-silencing experiments in mouse embryonic stem cells demonstrated that miRNA processing plays a major role in development. In the liver, Sekine et al. tested the consequence of DICER1 silencing by performing conditional knockout in hepatocytes. Remarkably, hepatocytes exhibiting DICER1-specific depletion displayed a gene expression profile indicative of cell growth and dedifferentiation into liver progenitors. Although the role of miRNAs in cell specification has been addressed in a number of tissues,[6, 24] little is known regarding the involvement of specific miRNAs in the control of hepatic development. miR-122 is probably an essential actor in liver ontogenesis, as suggested by its remarkable expression in the adult liver and its ability to induce CYPs in HCC cell lines. The case of miR-148a also appears of prime interest in cell lineage determination, as previously described in hematopoietic stem cell specification and myogenic differentiation. In the last case, Zhang et al. showed the positive role of miR-148a in skeletal muscle development by the translational repression of ROCK1, an inhibitor of myogenesis.
Consistent with our results, other studies have demonstrated that miRNAs can control expression of DNMTs. In the liver, miR-140 can target the 3'-UTR of DNMT1 and control nuclear factor kappa B activity. In addition, some splicing isoforms of DNMT3b have been found to be directly repressed by miR-148a. Conversely, epigenetic mechanisms are considered essential for miRNA regulation. The genomic sequence of miR-148a has been analyzed in a number of cancer cell lines with distinct tissue origins, as well as a large amount of CpG islands found in its promoter region. Thus, inactivation of miR-148a by DNA hypermethylation and DNMT1 overexpression has recently been demonstrated in pancreatic, gastric, and breast cancer. Consequently, the network of feedback between miRNAs and epigenetic pathways appears to form a complex regulatory system that is essential to organize gene expression profile and maintain cell integrity. miR-148a and DNMT1 certainly constitute a regulatory circuit that is disrupted in HCC tissues. On the one hand, overexpression of DNMT1 leads to hypermethylation of the promoter region of miR-148a, causing its silencing. On the other hand, miR-148a alteration reduces its silencing action on DNMT1, resulting in augmentation of DNMT1 expression and maintaining hypermethylation of the miR-148a promoter.
Our data finally suggest that miR-148a restoration may provide a valuable strategy for therapeutic applications by inhibiting c-Met expression and repressing HCC cell invasion. Pertinent studies previously indicated that the use of miRNA precursors could contribute to the development of promising miRNA-based therapeutic methods. For instance, Kota et al. showed that systemic administration of miR-26a in rodents led to a remarkable slowdown of HCC progression without toxicity. These observations suggest that the delivery of tumor-suppressor–type miRNAs, such as miR-148a and miR-122, which are highly expressed and therefore well tolerated in normal adult tissues, but lost in transformed cells, may provide a general strategy for miRNA replacement therapies. miR-148a also represents a valuable marker for the diagnosis and prognosis of HCC because its expression is frequently inhibited in liver cancer. Our observation that miR-148a alteration is not limited to the tumor site, but also affects the peritumoral nonneoplastic tissue, is noteworthy. This down-regulation is probably the consequence of the chronic inflammatory context inherent to hepatitis virus infection and liver fibrosis, which could represent an early event in CLDs, leading to augmentation of DNMT1 activity and aberrant DNA methylation. In this regard, Braconi et al. reported that the inflammation-associated cytokine, interleukin-6, regulates DNMT1 activity and methylation-dependent tumor-suppressor genes by modulating miR-148a/152 family expression in malignant cholangiocytes. Furthermore, another study showed that miR-152 is frequently down-regulated in HBV-related HCC, inducing DNMT1 augmentation and aberrant DNA methylation.
To conclude, our study demonstrates the existence of a dual role played by miR-148a in the liver. Importantly, we highlight a novel miRNA-mediated regulation mechanism in which miR-148a positively regulates hepatic differentiation by repressing DNMT1 expression. To our knowledge, this report is the first to demonstrate an effective promotion of the hepatospecific phenotype by modulating the expression of a single specific miRNA in a primary culture model using liver stem cells.
The authors thank A. Inoue, who offered excellent technical support throughout this study. The authors are also grateful to M. Kawamata, F. Takeshita, Y. Yoshioka, and T. Katsuda for their constructive comments on this work.